This Site makes heavy use of JavaScript

Either you have JavaScript disabled or your browser does not support JavaScript.

To work properly, this page requires JavaScript to be enabled. If you can enable it in your browser's preferences, you may have a better experience.

Efficacy Profile | Treating DVT/PE | Pradaxa® (dabigatran etexilate) Skip to main content
  • References:
  • 1. Data on File. Boehringer Ingelheim Pharmaceuticals, Inc.
  • 2. Pradaxa [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.
  • 3. Schulman S, Kearon C, Kakkar AK; for the RE‑COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342‑2352.
  • 4. Schulman S, Kakkar AK, Goldhaber SZ; for the RE‑COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764‑772.